According to a new report published by
Allied Market Research, titled, "Influenza Treatment Market by
Product Type, and Distribution Channel: Global Opportunity Analysis and
Industry Forecast, 2018–2026," the global influenza
treatment market size was valued at $862 million in 2018, and is expected to
reach $1.2 billion by 2026, registering a CAGR of 4.5% from 2019 to 2026.
Influenza drugs are defined as the medicines
which are employed for the treatment of patients suffering from influenza.
Influenza is a viral infection caused by influenza viruses such as type A, type
and type B. Furthermore, the virus is more serious in some group of people such
as pregnant women, older people, young children, and people suffering from
chronic diseases. Moreover, the infection manifests a wide range of clinical
symptoms such as headache, muscle aches, high fever, and vomiting. In addition,
severe cases of influenza can also lead to fatalities. Therefore, treatment of
the condition is necessary and requires use of anti-viral drugs such as
Peramivir, Zanamivir, Oseltamivir Phosphate, and Baloxavir Marboxil.
Rise in incidences of influenza across the
globe is the major factor that contributes to the growth of the influenza
treatment market. Furthermore, other factors such as surge in healthcare
expenditure and rise in R&D investments related to ant-viral drugs boost
the influenza treatment market growth. For instance, in 2018, F. Hoffmann-La
Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza.
Furthermore, Xofluza is the first new flu medicine with a novel proposed
mechanism of action. Therefore, this leads to availability of better treatment
option for the patients. However, adoption of influenza vaccines hampers the
growth of the influenza treatment market. Conversely, high growth potential
exhibited by developing economies due to surge in awareness related to early
detection and treatment of influenza is expected to offer lucrative
opportunities for the market during the forecast period.
The influenza treatment market size is
studied on the basis of product type, distribution channel, and region to
provide a detailed assessment. On the basis of product type, it is segmented
into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and
others. By distribution channel, it is bifurcated into retail pharmacy,
hospital pharmacy, and others. Region wise, it is analyzed across North America
(the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and
rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific),
and LAMEA (Brazil, South Africa, and rest of LAMEA).
By product, the market is classified into is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. The others segment acquired the largest share of the influenza treatment market in 2018. Furthermore, the segment is also anticipated to exhibit fastest growth during the forecast period. The growth of this segment is attributable to surge in prevalence of influenza virus infection across the globe. Furthermore, rise in awareness related to early diagnosis of the infection for better treatment is another major reason that contributes to the growth of the market.
By product, the market is classified into is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. The others segment acquired the largest share of the influenza treatment market in 2018. Furthermore, the segment is also anticipated to exhibit fastest growth during the forecast period. The growth of this segment is attributable to surge in prevalence of influenza virus infection across the globe. Furthermore, rise in awareness related to early diagnosis of the infection for better treatment is another major reason that contributes to the growth of the market.
By distribution channel, the influenza
treatment market is divided into retail pharmacy, hospital pharmacy, and
others. The retail pharmacy segment occupied the largest market share in 2018,
owing to factors such as rise in number of retail pharmacies across the globe.
In addition, other factors such as rise in awareness related to use of
influenza drugs is another major factor that contributes to the growth of the
market. The other factors which boost the growth of the market include surge in
the number of retail pharmacies across the globe which lead to easy
availability of influenza drugs. On the contrary, the others segment is
expected to witness the fastest growth rate during the forecast period due to
surge in use of internet across the globe, which allows consumers to buy drugs
online.
By region, North America accounted for the
major influenza treatment market share in 2018, and is expected to continue
this trend, owing to easy availability of influenza treatment. Moreover, surge
in incidences of influenza infection is another major reason that contributes
to the growth of this market. However, Asia-Pacific is estimated to register
the fastest growth rate during the forecast period, owing to increase in
awareness regarding the use of influenza drugs for the treatment of infection.
The constantly evolving life science industry in Asia-Pacific drives the growth
of the market in developing economies such as India, China, and Malaysia. . As
the constant development leads to surge in awareness related to the use of
influenza treatment.
KEY FINDINGS OF THE STUDY
- • Oseltamivir phosphate occupied more
than two-fifth share of the global influenza treatment market in 2018.
- • The others segment in distribution
channel pharmacy segment is anticipated to grow with the highest CAGR
throughout the forecast period.
- • The others segment in product type
accounted for more than two-fifth share of the market in 2018.
- • Asia-Pacific is anticipated to grow at
the highest rate during the analysis period, followed by LAMEA.
No comments:
Post a Comment